AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01921738
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
Trial: NCT01921738
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
Trial: NCT01921738
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
Trial: NCT00774826
Drug: R-CVP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
Trial: NCT00774826
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
Trial: NCT00774826
Drug: R-FM
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
Trial: NCT00540800
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: for metastatic breast cancer patients previously treated with anthracyclines
Trial: NCT00674609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
Trial: NCT00674609
Drug: THC Alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
Trial: NCT03870776
Drug: MAP4343
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral administration of MAP4343
Trial: NCT03870776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral administration of Placebo
Trial: NCT00560586
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff each nostril at bedtime
Trial: NCT00164021
Drug: Anti-reflux pharmacotherapy
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04392648
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide tablets orally.
Trial: NCT00816816
Drug: docetaxel, cisplatin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly.
Trial: NCT00132080
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
Trial: NCT02607176
Drug: Heweizhixie capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 #, Tid, Oral for 3 days
Trial: NCT02169089
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
Trial: NCT02169089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00476151
Drug: placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive placebo cream applied two times daily
Trial: NCT02748694
Drug: TAK-041 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-041 placebo-matching suspension or tablet.
Trial: NCT02475317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.
Trial: NCT01109979
Drug: Estradiol+MPA
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
Trial: NCT01109979
Drug: Estradiol+Drospirenone
RxNorm normalized name: drospirenone / estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
Trial: NCT00605137
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00201825
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Trial: NCT00361101
Drug: AMD11070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg PO BID (by mouth two times per day) for 10 days.
Trial: NCT04175301
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet also contains 80 mg magnesium
Trial: NCT03129009
Drug: Total intravenous anesthesia group
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
Trial: NCT03129009
Drug: Balanced anesthesia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
Trial: NCT03155932
Drug: APD334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD334 active treatment for 24 weeks.
Trial: NCT03097861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mcg administered orally BID
Trial: NCT03345407
Drug: Standard of care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
Trial: NCT00689416
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg, tablet, once daily for 3 months.
Trial: NCT00689416
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg, tablet, once daily for 3 months
Trial: NCT00576550
Drug: Urea
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea cream applied twice daily up to six months
Trial: NCT03693989
Drug: Prednefrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic
Trial: NCT01799603
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
Trial: NCT01017159
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
Trial: NCT01381445
Drug: GW870086 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to slightly coloured opaque cream
Trial: NCT01381445
Drug: GW870086 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to slightly coloured opaque cream
Trial: NCT01381445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to slightly coloured opaque cream
Trial: NCT00801606
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc 20 mg/day
Trial: NCT00801606
Drug: Micronutrient without zinc
RxNorm normalized name: zinc bandage without supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimineral 2 RDA
Trial: NCT00801606
Drug: Micronutrient with zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimineral 2 RDA and zinc 20 mg per day
Trial: NCT00801606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01984099
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
Trial: NCT00289952
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per standard of care.
Trial: NCT03883984
Drug: Cysteamine Bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
Trial: NCT02961283
Drug: ASN003 MTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
Trial: NCT04201275
Drug: HEC74647PA capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule administered orally once daily
Trial: NCT04201275
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC74647PA capsule matching placebo administered orally once daily
Trial: NCT03868202
Drug: Estradiol Transdermal Product
RxNorm normalized name: estradiol Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
Trial: NCT02436031
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg administered 2 hours before normal sleep time
Trial: NCT02436031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching desipramine administered 2 hours before normal sleep time
Trial: NCT02144285
Drug: LY3113593
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02144285
Drug: LY3113593
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02144285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02144285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01946256
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02098616
Drug: DCV/ASV/BMS-791325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
Trial: NCT02098616
Drug: DCV/ASV/BMS-791325 + RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
Trial: NCT04040634
Drug: Standard control of Systolic Blood Pressure (SBP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Trial: NCT01458717
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* 4 weeks rest, re-evaluation for resectability~* operation~* start maintenance chemotherapy within 4\~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle
Trial: NCT00955097
Drug: Definity®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definity® injections given both pre-ablation and post-ablation
Trial: NCT00113191
Drug: Veronate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00264654
Drug: BRL29060A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01815294
Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1 = Treatment A, Cycle 2 = Treatment B
Trial: NCT01815294
Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1 = Treatment B, Cycle 2 = Treatment A
Trial: NCT00070707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
Trial: NCT01018992
Drug: GSK561679
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK561679, oral administration, 350mg/day, 6 week administration
Trial: NCT01018992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, oral administration, 1 pill/day for 6 weeks
Trial: NCT04532333
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
Trial: NCT01241448
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT01241448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT02400749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be provided to sites in blister cards.
Trial: NCT03473665
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
Trial: NCT03473665
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
Trial: NCT03473665
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
Trial: NCT03473665
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
Trial: NCT01185340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01458288
Drug: TG-0054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
Trial: NCT00087516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
Trial: NCT00087516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
Trial: NCT00612521
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
Trial: NCT02020200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01581840
Drug: radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
Trial: NCT03315936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT00329121
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03491098
Drug: prednisolone sodium phosphate 15mg
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: three times per day for 1 week then gradual withdrawal over 2 weeks
Trial: NCT00186498
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
Trial: NCT01147289
Drug: Dextralgen
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
Trial: NCT01147289
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
Trial: NCT04371406
Drug: Hydroxychloroquine and Azithromycin
RxNorm normalized name: cefixime and azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
Trial: NCT01039506
Drug: CPT-11 based regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02836158
Drug: R-IDARAM plus intrathecal chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
Trial: NCT00480896
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT00890175
Drug: Inhaled placebo @ 2 & 10 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 2 doses, 10 hours apart
Trial: NCT02918500
Drug: Nicoderm Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy patch
Trial: NCT00594191
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
Trial: NCT00594191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with the same characteristics of the drug and at the same dose
Trial: NCT00021034
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00113360
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of 5 or 10 mg by mouth daily.
Trial: NCT02238717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching oral placebo
Trial: NCT00792506
Drug: ITF2357
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
Trial: NCT00416442
Drug: RSV604
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01725386
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablet(s) administered according to prescribing information
Trial: NCT00006232
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01216163
Drug: Novel Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)